Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Oct;36(10):2075–2079. doi: 10.1128/aac.36.10.2075

Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.

C A Knupp 1, F M Graziano 1, R M Dixon 1, R H Barbhaiya 1
PMCID: PMC245458  PMID: 1444287

Abstract

The potential pharmacokinetic interactions between didanosine, an acid-labile antiretroviral agent, and ranitidine, an H2-receptor antagonist, were evaluated by a crossover study of 12 male patients seropositive for the human immunodeficiency virus. Single oral doses of 375 mg of didanosine, formulated as a citrate-phosphate-buffered sachet, or of 150 mg of ranitidine were administered alone or in combination (ranitidine was given 2 h prior to didanosine). Serial blood samples and total urinary output were collected after each treatment and analyzed for didanosine and/or ranitidine by validated high-performance liquid chromatography-UV assay methods. Pharmacokinetic parameters were calculated by noncompartmental methods. There were significant increases in mean area under the curve from time zero to infinity and mean urinary recovery for didanosine given in combination with ranitidine compared with those for didanosine alone. There were no significant differences between didanosine coadministered with ranitidine and didanosine alone in the respective mean peak concentrations in plasma, times to peak, elimination half-lives, or renal clearances. The mean area under the curve for ranitidine given with didanosine was significantly less than that for ranitidine given alone. There were no significant differences between the mean peak concentrations in plasma, times to peak, elimination half-lives, renal clearances, or urinary recovery values for ranitidine coadministered with didanosine and values for ranitidine given alone. These data demonstrate that administration of didanosine 2 h after ranitidine will result in a minor increase in the bioavailability of didanosine. A modification in the dose of didanosine or ranitidine is not necessary if the dose of ranitidine precedes that of didanosine by 2 h.

Full text

PDF
2075

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia G., Cooney D. A., Mitsuya H., Fridland A., Flora K. P., Hao Z., Dalal M., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987 Nov 15;36(22):3797–3800. doi: 10.1016/0006-2952(87)90440-0. [DOI] [PubMed] [Google Scholar]
  2. Albin H., Vinçon G., Begaud B., Bistue C., Perez P. Effect of aluminum phosphate on the bioavailability of ranitidine. Eur J Clin Pharmacol. 1987;32(1):97–99. doi: 10.1007/BF00609966. [DOI] [PubMed] [Google Scholar]
  3. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCaffrey R. P., Liebman H. A. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med. 1990 May 10;322(19):1340–1345. doi: 10.1056/NEJM199005103221902. [DOI] [PubMed] [Google Scholar]
  4. Fimmel C. J., Etienne A., Cilluffo T., von Ritter C., Gasser T., Rey J. P., Caradonna-Moscatelli P., Sabbatini F., Pace F., Bühler H. W. Long-term ambulatory gastric pH monitoring: validation of a new method and effect of H2-antagonists. Gastroenterology. 1985 Jun;88(6):1842–1851. doi: 10.1016/0016-5085(85)90009-5. [DOI] [PubMed] [Google Scholar]
  5. Garg D. C., Weidler D. J., Eshelman F. N. Ranitidine bioavailability and kinetics in normal male subjects. Clin Pharmacol Ther. 1983 Apr;33(4):445–452. doi: 10.1038/clpt.1983.60. [DOI] [PubMed] [Google Scholar]
  6. Grant S. M., Langtry H. D., Brogden R. N. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Jun;37(6):801–870. doi: 10.2165/00003495-198937060-00003. [DOI] [PubMed] [Google Scholar]
  7. Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
  8. Knupp C. A., Shyu W. C., Dolin R., Valentine F. T., McLaren C., Martin R. R., Pittman K. A., Barbhaiya R. H. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther. 1991 May;49(5):523–535. doi: 10.1038/clpt.1991.63. [DOI] [PubMed] [Google Scholar]
  9. Knupp C. A., Stancato F. A., Papp E. A., Barbhaiya R. H. Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography. J Chromatogr. 1990 Nov 30;533:282–290. doi: 10.1016/s0378-4347(00)82215-x. [DOI] [PubMed] [Google Scholar]
  10. Lambert J. S., Seidlin M., Reichman R. C., Plank C. S., Laverty M., Morse G. D., Knupp C., McLaren C., Pettinelli C., Valentine F. T. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333–1340. doi: 10.1056/NEJM199005103221901. [DOI] [PubMed] [Google Scholar]
  11. Mihaly G. W., Marino A. T., Webster L. K., Jones D. B., Louis W. J., Smallwood R. A. High dose of antacid (Mylanta II) reduces bioavailability of ranitidine. Br Med J (Clin Res Ed) 1982 Oct 9;285(6347):998–999. doi: 10.1136/bmj.285.6347.998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Riegelman S., Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm. 1980 Oct;8(5):509–534. doi: 10.1007/BF01059549. [DOI] [PubMed] [Google Scholar]
  14. Shyu W. C., Knupp C. A., Pittman K. A., Dunkle L., Barbhaiya R. H. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):503–507. doi: 10.1038/clpt.1991.175. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES